Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Go back to Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
(NASDAQ: PLRZ) Delayed: 15.31 +0.92 (6.39%)
Previous Close $14.39    52 Week High
Open $14.39    52 Week Low
Day High $15.31    P/E N/A 
Day Low $13.59    EPS
Volume 92,925